CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | King-Jones Heidy See Remarks | Option exercise 10b5-1 | +28,933 | $14.50 | $420K | 31,778 |
| 2026-10-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −400 | $89.24 | $36K | 31,378 |
| 2026-10-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −16,605 | $90.35 | $1.5M | 14,773 |
| 2026-10-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −7,228 | $91.35 | $660K | 7,545 |
| 2026-10-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −2,100 | $92.70 | $195K | 5,445 |
| 2026-10-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −2,600 | $93.46 | $243K | 2,845 |
| 2026-10-01 | King-Jones Heidy See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −28,933 | 482,478 | ||
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −600 | $89.14 | $53K | 551,940 |
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −2,683 | $90.10 | $242K | 549,257 |
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −2,638 | $91.49 | $241K | 546,619 |
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,989 | $92.31 | $368K | 542,630 |
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −4,990 | $93.37 | $466K | 537,640 |
| 2026-10-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −100 | $93.91 | $9K | 537,540 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 87,262 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −600 | $89.07 | $53K | 86,662 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −1,500 | $90.27 | $135K | 85,162 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −2,100 | $91.92 | $193K | 83,062 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −3,071 | $92.95 | $285K | 79,991 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −229 | $93.57 | $21K | 79,762 |
| 2026-10-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 312,357 |
Page 1 of 12 · 222 trades